Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
While I take your point I certainly hope revenue exceeds 650 million and by quite a lot. Is that Amarin's 2021 estimate?
Last update for that info per the link was Dec 9 2020 so they stopped taking new patients months ago.
Per unsourced post on Yahoo the eap program for zyesami is winding down. No new patients will be accepted into the program. FWIW
Interesting article on generic supply issues. Apologies if it's been posted before.
https://www.google.com/amp/s/www.zeebiz.com/market-news/news-dr-reddys-laboratories-share-price-jefferies-maintains-buy-rating-on-the-stock-152716/amp
There is literally no relevant info in that filing, just the intro. Wikipedia describes an s1 filing as being 8 pages long but I did find this in the article:
Under the JOBS Act, it has been possible since April 2012 for "emerging growth companies" to file a Form S-1 on a confidential basis, only making the contents public 21 days prior to the road show for the IPO. This quickly became a popular method for even established companies (such as Manchester United and MGM Studios) to conduct securities offerings.[1]
If Merck buys NWBO with a share issue you'll automatically get Merck shares.
The article you posted is about Acer. SMH
It's not a clue, it's a breadcrumb dropped to entice people to invest in Acer.
That is sponsored content. In other words, the website is being paid to host the content provided by another party. I'm not impressed by this article and wouldn't purchase Acer stock based on the content.
It hasn't affected the price on the Swiss exchange which is up just a bit. We have until 16 March to find out I guess as the placement won't be finalized until then. I take it as a vote of confidence.
You're tryn2 hard. Give it a rest.
If it was a stop loss raid (that's what it looks like from the chart) we can expect it to be reenacted when U.S. trading opens. Gonna be a rough day I think .
New spherical nucleic acid 'drug' kills tumor cells in humans with glioblastoma
https://medicalxpress.com/news/2021-03-spherical-nucleic-acid-drug-tumor.html
A little work with a calculator reveals the stock was worth a tiny fraction of a penny before the split. You have chosen your screen name here wisely
Apart from the Brit reactions it looks like advertising during that Oprah special got exposure rivaling the super bowl.
You are correct. But with any luck those trials will provide positive results about the time the current cvd patents expire. For the record, I believe there are already better treatments for prostate cancer in the pipeline but they may be more invasive.
Time for Amarin to issue a generic vascepa under the old label then.;)
Wouldn't that depend on how a doctor wrote the scrip? Even if tg is greater than 500 if the scrip is written for cvd then the patient would receive Vascepa.
Amarin has a patent for prostate cancer treatment.
Somehow missed this. Was not expecting that patent to grant anytime soon. But it did. $AMRN #ProstateCancer pic.twitter.com/x0R2HhMYBQ
— TerraPharma (@TerraPharma1) March 7, 2021
Amarin and prostate cancer. I just saw this on terra pharma's Twitter. Apologies if this has been posted earlier.
Somehow missed this. Was not expecting that patent to grant anytime soon. But it did. $AMRN #ProstateCancer pic.twitter.com/x0R2HhMYBQ
— TerraPharma (@TerraPharma1) March 7, 2021
A quick note on the Wright brothers. Even today their engineering ability is widely recognized. Their notes and diagrams indicate a firm grasp of math and design. The myth that they were merely two bicycle mechanics who stumbled on the secret to flying is just that, a myth.
Could be the same guy who frequented the yahoo board with that moniker. If they're one and the same he's a useless pumper.
Someone mentioned they suspected a fund might be unwinding their position here. It certainly has that smell. Are the Baker Brothers still invested here?
Do we know the results of the Gilead NASH trial using Amarin yet?
There are a lot of other diseases zyesami could help with for sure but those would need additional trials. If rlftf doesn't have funds to conduct the studies I don't see how they can conduct the studies and as far as I know the only way to obtain those funds is to get the eua.
I have cautiously reentered this stock as the price has dropped this week. If it goes below six I will buy a bit more. It's undervalued at this point. I believe the reason the price has dropped this week is JT's continued emphasis on going it alone in Europe but as has been repeatedly pointed out over the past year, not taking on a partner leaves the door open for a buyout. Even if that doesn't happen though I believe there is upside at this price in a year.
New covid cases have dropped by 21% since January. Deaths have dropped by 17 percent.
No. What I'm saying is covid is fading as a health issue because of the vaccines. The need for zyesami is fading as well.
And the inhaled study is for covid which probably won't even be an issue in August. The timeline for rlftf is growing very short imo.
That would require lengthy new studies and money to fund them.
The 60 day data has been in their hands for a week now. They know what they've got and we're waiting on the completed data analysis. Hopefully we see it this week.
That article deals with testing but it does illustrate the fact that the FDA is overwhelmed and not communicating with applicants. Who knows if that same situation is occurring with respect to evaluating therapeutics. Their focus does seem to be vaccines.
Let me Qantify that for you. Qantas has had zero crashes since 1951 when they were still a small domestic carrier. And Qantas has no u in the name.
The major concern for me is that it's Merck. They have clout and we don't .
COVID-19 oxygen emergency impacting more than half a million people in low- and middle-income countries every day, as demand surges
https://reliefweb.int/report/world/covid-19-oxygen-emergency-impacting-more-half-million-people-low-and-middle-income
Either that or the FDA dances to big pharma's tune.
If we can't sustain the closing price from yesterday based on the pr news then I question what effect an actual eua will have on the price. After all, the info in the pr virtually guarantees an eua will be issued.
That's the best writeup I've seen regarding rlftf, neurorx and zyesami.
Bringing it back down into the close.
I think journalists might call CEO's and tell them they're going to print an article and ask them for comment.